Schnitzler Syndrome
9
2
2
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
11.1%
1 terminated out of 9 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (9)
A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients With Schnitzler's Syndrome
AutoInflammatory Disease Alliance Registry (AIDA)
Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome
Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome
Ilaris (Canakinumab) in the Schnitzler Syndrome
Ilaris® Effects in Schnitzler Syndrome (ILESCH)
Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors
Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)
Efficacy and Safety of Canakinumab in Schnitzler Syndrome